Completed PHASE1 INTERVENTIONAL 2-arm NCT01828827

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-003)

A Phase 1, Randomized, Balanced, Single-Dose, Two-Treatment, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects

Sponsor: Global Alliance for TB Drug Development

Conditions Tuberculosis

Interventions PA-824 1000 mg

Updated 6 times since 2017 Last updated: Jan 12, 2016 Started: Mar 31, 2007 Primary completion: Mar 31, 2007 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Tuberculosis and is currently completed. Global Alliance for TB Drug Development leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Global Alliance for TB Drug Development

Data source: Global Alliance for TB Drug Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States